| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Genomics Institute of the Novartis Research Foundation, San Diego, California 92121 [J. B. W., L. M. S., S. G. K., G. M. H.]; The Scripps Research Institute, La Jolla, California 92037 [A. I. S.]; Department of Pathology, University of California, San Diego, La Jolla, California 92093 [J. W-R.]; and Department of Pathology, University of Virginia, Charlottesville, Virginia 22908 [C. A. M., H. F. F.]
 |
ABSTRACT |
|---|
 Top ABSTRACT IntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
|
Introduction |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
A molecular understanding of prostate cancer development and progression is an important step toward the identification of additional biomarkers with increased specificity for invasive prostate cancer and of new tumor-specific therapeutic targets. Previous systematic interrogations of gene expression levels in human cancers by microarray hybridization (6) suggest that this is a broad and efficient approach toward identifying candidate markers and drug targets. Here, we analyzed the expression levels of more than 8900 different human genes in a set of normal and malignant prostate tissues. Quantitative and qualitative differences in gene expression seen in tissue samples led to a molecular definition of prostate cancer. We identified several genes as overexpressed in most or all of the tumors. Some of these may form the basis for new diagnostic or therapeutic approaches as well as provide insight into prostate tumor development or behavior.
|
Materials and Methods |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
Tissue Procurement, cRNA Synthesis, and Hybridization to Oligonucleotide Arrays.
The use of human tissue samples at the University of Virginia (UVA) was approved by the UVA Human Investigation Committee. Fresh samples of adenocarcinoma were obtained from men with elevated PSA levels. H&E-stained sections from prostatectomy specimens or (in one case) from a lymph node metastasis were examined to assess the relative amounts of tumor, benign epithelium, stroma, and lymphocytes. Tissues containing cancer were trimmed to enrich for neoplastic cells. All of the samples were stored at -80°C before processing for microarray analysis. The set of prostate tissues included 23 primary cancer tissues, 1 lymph node metastasis, and 9 nonneoplastic tissues. Eight of the cancers were paired with normal tissue obtained from the same patient. One cancer tissue (case 13) was divided and processed as two independent samples. In each case, several milligrams of tissue were sharply dissected and homogenized with a rotary homogenizer (Omni International) in RNeasy lysis buffer (Qiagen). RNA was prepared from tissues and cells using the RNeasy Mini kit (Qiagen). mRNAs from T-lymphoblastic MOLT4 and myeloleukemic HL60 cells were purchased (Clontech), and RNA from endothelial cells and from three individual isolates of activated B-cells were gifts from Drs. Akira Kawamura (The Scripps Research Institute, La Jolla, CA) and Michael Cooke (Genomics Institute of The Novartis Research Foundation, San Diego, CA) respectively. Labeled cRNA was prepared and hybridized to oligonucleotide arrays ("U95a"; Affymetrix) as described previously (7)
.
Data Analysis.
Scanned image files were visually inspected for artifacts and analyzed with GENECHIP 3.1 (Affymetrix). Each image was then scaled to an average hybridization intensity of 200, which corresponds to 
3–5 transcripts per cell (7)
. The hybridization intensity for each gene was ranked according to intersample variability (SD), and 3530 genes with the most variable expression across all of the samples were median-centered and normalized with respect to other genes in the sample and corresponding genes in other samples. Genes and samples were subjected to hierarchical clustering essentially as described previously (8)
. Differential expression of genes in benign and malignant prostate tissues was estimated using an algorithm (9)
based on equally weighted contributions from the difference of hybridization intensities (µTumor–µNormal), the quotient of hybridization intensities (µTumor/µNormal), and the result of an unpaired t test between expression levels in tumor and normal tissues. The genes were scored with respect to each of the three metrics, then ranked according to the sum of the three scores.
Reverse Transcription-PCR Analysis of hepsin and MIC-1 Expression.
cDNA was prepared using 1 µg of total RNA isolated from prostate tissues. Primers used to amplify specific gene products were: hepsin sense, 5'-CGGGACCCCAACAGCGAGGAGAAC-3'; hepsin antisense, 5'-TCGGGGTAGCCAGCACAGAACATC-3'; MIC-1 sense, 5'-CGCGCAACGGGGACGACT-3'; and MIC-1 antisense, 5'-TGAGCACCATGGGATTGTAGC-3'. PCR conditions for hepsin and MIC-1 comprised 95°C for 10 min, 30 cycles of 95°C for 30 s, 55°C for 30 s (annealing), and 72°C for 30 s, and a final elongation step of 72°C for 7 min. All of the PCR reactions used a volume of 20 µl, with 1 unit of AmpliTaq Gold (Perkin-Elmer). Amplification products (10 µl) were separated by 2% agarose gel electrophoresis.
Immunohistochemistry.
The avidin-biotin immunoperoxidase method was performed on deparaffinized zinc formalin-fixed, paraffin-embedded sections. Slides placed in citrate buffer were heated with a microwave for 20 min prior to the application of the anti-FASN antibody for 1 h at room temperature.
|
Results and Discussion |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
8920 different genes. In total, we hybridized 55 RNA samples derived from 25 prostate cancer tissues (24 unique samples), 9 nonmalignant prostate tissues, and 21 cell line samples (18 unique lines).3
Clinical and pathological information on the tumors is detailed in Table 1
.
|
. As expected, independently prepared samples of tumor 13 (13A and 13B) and replicate samples of LNCaP cells and HUVECs were highly correlated, demonstrating the overall reproducibility of the technique. This analysis revealed a major division between cells grown in vitro and the human tissue specimens, with highly divergent gene expression patterns. Within the "tissue" branch of the dendrogram, samples were further subdivided into two distinct groups of normal and malignant samples.
|
largely reflected the embryological origin of the cells. For example, profiles of activated B cells from three different donors were highly correlated with one another and with cells derived from two hematological cancers (MOLT4 and HL60). Six mesenchymal lines derived from normal or malignant prostates of different individuals (designated as BPHF, PrSC, or CAF) were highly related. Similarity was also seen among LNCaP cells grown in the presence or absence of dihydrotestosterone (DHT).
Expression of Genes in Malignant and Cancer-associated Cell Types.
We identified a striking group of 400 genes as being highly and specifically expressed in malignant samples (Fig. 1b
, malignant luminal epithelial; expanded in MALIGNANT LUMINAL, Fig. 1c
). Among this group, we identified keratins 8 and 18, which strongly suggested that this cluster of genes signified malignant luminal epithelium within the cancer tissue (10)
. We identified several other clusters of genes for which expression levels were similar in some of the cells and tissues. These clusters suggested the presence of varying amounts of B cells, normal basal epithelial cells, and stromal fibroblasts within normal and tumor tissues (Fig. 1c
, B-CELL, BA, and STROMAL, respectively). The varying proportion of cancer-associated cells implied by expression profiling was consistent with our histological estimates of these cell types in each of the tissue samples. High expression of B-cell genes in normal and malignant samples from cases 9 and 10 (Fig. 1c
, B-CELL) was consistent with histologically diagnosed prostatitis in these patients. A fourth group of genes was highly expressed in LNCaP cells and in most of the tumor samples (Fig. 1b
and METAB, Fig. 1c
) and included multiple genes the products of which are involved in intermediary metabolism, such as ATP synthase and cytochrome C oxidase. Expression of genes within this cluster likely reflects accelerated metabolism of the malignant cells.
Genes with Potential Diagnostic and Therapeutic Utility in Prostate Cancer.
The strong molecular distinction between normal and tumor tissues and the relative homogeneity of gene expression in malignant epithelial cells when compared with normal prostate samples suggested that we could identify genes that were overexpressed in the majority of tumors. The tumor samples examined here contained, on average, about twice as many epithelial cells as the normal tissues. Thus, we focused on methods that could rank highest those genes with the greatest and most uniform differences in gene expression. We used a metric that would take into account the equal importance of average hybridization intensities and fold differences, as well as uniformity of expression within a tissue type (penalizing genes with broad and overlapping ranges of expression; Ref. 9
). This metric returned genes the expression of which was generally low in normal tissues, elevated in tumors (average, >5-fold for the top 20 genes; Fig. 2
) with nonoverlapping expression ranges. Among the 20 highest scoring genes were ones encoding known tumor markers such as the carcinoma-associated antigen GA733–2 (TACSTD1) and FASN. We also identified MIC-1, which encodes a secreted cytokine (11)
, and hepsin, which encodes a membrane-bound extracellular serine protease involved in cell growth control (12)
. Expression levels of PSA, MIC-1, and hepsin transcripts are given in Table 1
.
|
. Second, the public "Gene-to-Tag" database4
was queried for differential expression of the genes in Fig. 2
in normal and prostate cancer samples. Reliable estimates of the expression levels in a single microdissected pair of normal and malignant prostate samples were available for 12 of the 20 genes. Of these 12, 10 showed >5-fold overexpression in cancer tissue. Third, we stained tissue sections with a monoclonal antibody against FASN (13)
and found strong and specific immunopositivity in malignant epithelium in all 10 cases of prostate cancer that we examined (Fig. 4)
.
|
|
) resulted from the initial analysis of 3530 genes the expression of which varied most across normal tissues, malignant tissues, and cell lines (Fig. 1b)
. To better estimate the extent of the similarity among prostate cancers, we selected 788 of these genes the expression of which was inferred to be specific to the malignant cells. Clustering of the data showed a dichotomy among the tumors, which was largely attributable to differential expression of a group of ribosomal genes (Fig. 1a
, Ribo). This division roughly corresponded to the degree of differentiation among the tumors, with significantly higher Gleason scores (P < 0.01) in the tumor samples with lower ribosomal gene expression. We next sought genes the expression of which might better differentiate low- and high-grade tumors. ANOVA was performed on tumors divided into subgroups with different Gleason scores (group 1: Gleason score, 5 or 6; group 2: Gleason score, 7; group 3: Gleason score, 8 or 9). Among the 20 most significantly different genes identified by this method, we found high expression of IGFBP-2 and IGFBP-5 in group 3 (Gleason score, 8 or 9) compared with groups 1 and 2 (Gleason scores, 5, 6, or 7; data not shown). Both of these genes have been reported as elevated in high-grade tumors (14)
.
In this study, we exploited the observed similarities among prostate tumors to identify genes with potential clinical use. The list of genes highly ranked by our metric (Fig. 2)
is functionally diverse and includes several genes involved in fatty acid, sugar, nucleotide, and steroid intermediary metabolism. FASN up-regulation is consistent with a previous report (15)
and is of particular interest because pharmacological inhibition of FASN results in dose-dependent growth inhibition in a prostate cancer xenograft model (13)
. The serine protease, hepsin, which we and others (16)
find up-regulated in all of the primary tumors examined, is a potential drug target (17)
. The potential benefit of hepsin inhibition is shown by growth arrest induced in hepatoma cells using anti-hepsin antibodies and antisense oligonucleotides (12)
. We also found overexpression of the gene encoding the secreted cytokine MIC-1, a member of the transforming growth factor-ß superfamily (18)
in 21 of the 24 cancers examined (Table 1)
. High MIC-1 levels are found in amniotic (19)
and cerebrospinal (20)
fluids, and recent studies suggest its overexpression in the serum of patients with metastatic breast, colon, and prostate carcinomas.5
We profiled androgen-dependent and -independent prostate cancer-derived cells grown in vitro to evaluate the fidelity with which these cells replicate features of malignant prostate cells in vivo. Overall, we found only a small number of genes with concordant expression in cell lines and malignant tissues, which suggests that these cell lines have lost many features that characterize prostate cancer in vivo. Thus, it is not surprising that many of the genes that we identified as overexpressed in this study have not been reported as overexpressed in prostate cancer cell types. The fact that we, and others (16) , now find genes such as hepsin to be overexpressed in all of the primary tumors examined underscores the usefulness of profiling primary tumors and the likelihood that these data will provide new insight into prostate cancer.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 To whom requests for reprints should be addressed, at Genomics Institute of the Novartis Research Foundation, 3115 Merryfield Row, San Diego, CA 92121. Phone: (858) 812-1522; Fax: (858) 812-1746; E-mail: hampton{at}gnf.org 
2 The abbreviations used are: FASN, fatty acid synthase; HUVEC, human umbilical vein endothelial cell; PSA, prostate-specific antigen.
3 The complete dataset is available on our web site, address: http://www.gnf.org/cancer/prostate.
4 Internet address: http://www.ncbi.nlm.nih.gov/SAGE/.
5 S. N. Breit, personal communication.
Received 4/23/01. Accepted 7/ 5/01.
|
REFERENCES |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResults and DiscussionREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  W. Li, B.-E. Wang, P. Moran, T. Lipari, R. Ganesan, R. Corpuz, M. J.C. Ludlam, A. Gogineni, H. Koeppen, S. Bunting, et al. Pegylated Kunitz Domain Inhibitor Suppresses Hepsin-Mediated Invasive Tumor Growth and Metastasis Cancer Res., November 1, 2009; 69(21): 8395 - 8402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zhang, C. Wu, E. Blanzieri, Y. Zhou, Y. Wang, W. Du, and Y. Liang Methods for labeling error detection in microarrays based on the effect of data perturbation on the regression model Bioinformatics, October 15, 2009; 25(20): 2708 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhao, B. Y. Lee, D. A. Brown, M. P. Molloy, G. M. Marx, N. Pavlakis, M. J. Boyer, M. R. Stockler, W. Kaplan, S. N. Breit, et al. Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling Cancer Res., October 1, 2009; 69(19): 7696 - 7703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Q. Xia, M. McClelland, S. Porwollik, W. Song, X. Cong, and Y. Wang WebArrayDB: cross-platform microarray data analysis and public data repository Bioinformatics, September 15, 2009; 25(18): 2425 - 2429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Arredouani, B. Lu, M. Bhasin, M. Eljanne, W. Yue, J.-M. Mosquera, G. J. Bubley, V. Li, M. A. Rubin, T. A. Libermann, et al. Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer Clin. Cancer Res., September 15, 2009; 15(18): 5794 - 5802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cheng, K. Shen, C. Song, J. Luo, and G. C. Tseng Ratio adjustment and calibration scheme for gene-wise normalization to enhance microarray inter-study prediction Bioinformatics, July 1, 2009; 25(13): 1655 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lupien and M. Brown Cistromics of hormone-dependent cancer Endocr. Relat. Cancer, June 1, 2009; 16(2): 381 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Z. Qian, C.-Y. Huang, C. A. O'Brien, I. M. Coleman, M. Garzotto, L. D. True, C. S. Higano, R. Vessella, P. H. Lange, P. S. Nelson, et al. Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies Clin. Cancer Res., May 1, 2009; 15(9): 3135 - 3142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Monami, V. Emiliozzi, A. Bitto, F. Lovat, S.-Q. Xu, S. Goldoni, M. Fassan, G. Serrero, L. G. Gomella, R. Baffa, et al. Proepithelin Regulates Prostate Cancer Cell Biology by Promoting Cell Growth, Migration, and Anchorage-Independent Growth Am. J. Pathol., March 1, 2009; 174(3): 1037 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. J. Arnoldussen, P. I. Lorenzo, M. E. Pretorius, H. Waehre, B. Risberg, G. M. Maelandsmo, H. E. Danielsen, and F. Saatcioglu The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1-Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer Cancer Res., November 15, 2008; 68(22): 9255 - 9264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Kelly, S. R. Setlur, R. Ross, R. Anbazhagan, P. Waterman, M. A. Rubin, and R. Weissleder Detection of Early Prostate Cancer Using a Hepsin-Targeted Imaging Agent Cancer Res., April 1, 2008; 68(7): 2286 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-K. Kim, J. J. Lee, Y. Yang, K.-H. You, and J.-H. Lee Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells Carcinogenesis, April 1, 2008; 29(4): 704 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. McCabe, D. D. Spyropoulos, D. Martin, and C. S. Moreno Genome-Wide Analysis of the Homeobox C6 Transcriptional Network in Prostate Cancer Cancer Res., March 15, 2008; 68(6): 1988 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Wallace, R. L. Prueitt, M. Yi, T. M. Howe, J. W. Gillespie, H. G. Yfantis, R. M. Stephens, N. E. Caporaso, C. A. Loffredo, and S. Ambs Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men Cancer Res., February 1, 2008; 68(3): 927 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fritah, C. Saucier, O. De Wever, M. Bracke, I. Bieche, R. Lidereau, C. Gespach, S. Drouot, G. Redeuilh, and M. Sabbah Role of WISP-2/CCN5 in the Maintenance of a Differentiated and Noninvasive Phenotype in Human Breast Cancer Cells Mol. Cell. Biol., February 1, 2008; 28(3): 1114 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Vavere, S. J. Kridel, F. B. Wheeler, and J. S. Lewis 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer J. Nucl. Med., February 1, 2008; 49(2): 327 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sauvageau, M. Miller, S. Lemieux, J. Lessard, J. Hebert, and G. Sauvageau Quantitative expression profiling guided by common retroviral insertion sites reveals novel and cell type specific cancer genes in leukemia Blood, January 15, 2008; 111(2): 790 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Oldberg, S. Kalamajski, A. V. Salnikov, L. Stuhr, M. Morgelin, R. K. Reed, N.-E. Heldin, and K. Rubin Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma PNAS, August 28, 2007; 104(35): 13966 - 13971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Wong, H. Haack, J. L. Kissil, M. Barry, R. T. Bronson, S. S. Shen, C. A. Whittaker, D. Crowley, and R. O. Hynes Protein 4.1B suppresses prostate cancer progression and metastasis PNAS, July 31, 2007; 104(31): 12784 - 12789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Bjartell, H. Al-Ahmadie, A. M. Serio, J. A. Eastham, S. E. Eggener, S. W. Fine, L. Udby, W. L. Gerald, A. J. Vickers, H. Lilja, et al. Association of Cysteine-Rich Secretory Protein 3 and {beta}-Microseminoprotein with Outcome after Radical Prostatectomy Clin. Cancer Res., July 15, 2007; 13(14): 4130 - 4138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Tai and W. Pan Incorporating prior knowledge of predictors into penalized classifiers with multiple penalty terms Bioinformatics, July 15, 2007; 23(14): 1775 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Song, J. Bedo, K. M. Borgwardt, A. Gretton, and A. Smola Gene selection via the BAHSIC family of algorithms Bioinformatics, July 1, 2007; 23(13): i490 - i498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Selander, D. A. Brown, G. B. Sequeiros, M. Hunter, R. Desmond, T. Parpala, J. Risteli, S. N. Breit, and A. Jukkola-Vuorinen Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 532 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Turley, E. C. Finger, N. Hempel, T. How, T. A. Fields, and G. C. Blobe The Type III Transforming Growth Factor-{beta} Receptor as a Novel Tumor Suppressor Gene in Prostate Cancer Cancer Res., February 1, 2007; 67(3): 1090 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Meinhold-Heerlein, D. Bauerschlag, Y. Zhou, L. M. Sapinoso, K. Ching, H. Frierson Jr., K. Brautigam, J. Sehouli, E. Stickeler, D. Konsgen, et al. An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 458 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Tozlu, I Girault, S Vacher, J Vendrell, C Andrieu, F Spyratos, P Cohen, R Lidereau, and I Bieche Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach Endocr. Relat. Cancer, December 1, 2006; 13(4): 1109 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Knudsen Migrating with Myosin VI Am. J. Pathol., November 1, 2006; 169(5): 1523 - 1526. [Full Text] [PDF]
|
|
|
|
|
|
T. Manoli, N. Gretz, H.-J. Grone, M. Kenzelmann, R. Eils, and B. Brors Group testing for pathway analysis improves comparability of different microarray datasets Bioinformatics, October 15, 2006; 22(20): 2500 - 2506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Moran, W. Li, B. Fan, R. Vij, C. Eigenbrot, and D. Kirchhofer Pro-urokinase-type Plasminogen Activator Is a Substrate for Hepsin J. Biol. Chem., October 13, 2006; 281(41): 30439 - 30446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Teschendorff, A. Naderi, N. L. Barbosa-Morais, and C. Caldas PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer Bioinformatics, September 15, 2006; 22(18): 2269 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Madoz-Gurpide, P. Lopez-Serra, J. L. Martinez-Torrecuadrada, L. Sanchez, L. Lombardia, and J. I. Casal Proteomics-based Validation of Genomic Data: Applications in Colorectal Cancer Diagnosis Mol. Cell. Proteomics, August 1, 2006; 5(8): 1471 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J.M. Hendriksen, N. F.J. Dits, K. Kokame, A. Veldhoven, W. M. van Weerden, C. H. Bangma, J. Trapman, and G. Jenster Evolution of the Androgen Receptor Pathway during Progression of Prostate Cancer. Cancer Res., May 15, 2006; 66(10): 5012 - 5020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Li, M. Szabolcs, J. D. Terwilliger, and A. Efstratiadis Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene Carcinogenesis, May 1, 2006; 27(5): 1054 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Liu, S. Ramachandran, M. Ali Seyed, C. D. Scharer, N. Laycock, W. B. Dalton, H. Williams, S. Karanam, M. W. Datta, D. L. Jaye, et al. Sex-determining region y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res., April 15, 2006; 66(8): 4011 - 4019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-R. Li, J. Wang-Rodriguez, T. M. Nair, J. M. Yeakley, Y.-S. Kwon, M. Bibikova, C. Zheng, L. Zhou, K. Zhang, T. Downs, et al. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res., April 15, 2006; 66(8): 4079 - 4088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-A. Xuan, D. Schneider, P. Toy, R. Lin, A. Newton, Y. Zhu, S. Finster, D. Vogel, B. Mintzer, H. Dinter, et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res., April 1, 2006; 66(7): 3611 - 3619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Vanaja, K. V. Ballman, B. W. Morlan, J. C. Cheville, R. M. Neumann, M. M. Lieber, D. J. Tindall, and C. Y.F. Young PDLIM4 Repression by Hypermethylation as a Potential Biomarker for Prostate Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1128 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nanni, C. Priolo, A. Grasselli, M. D'Eletto, R. Merola, F. Moretti, M. Gallucci, P. De Carli, S. Sentinelli, A. M. Cianciulli, et al. Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate Cancer Mol. Cancer Res., February 1, 2006; 4(2): 79 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Duggan, W. M. Gallagher, E. J.P. Fox, M. M. Abdel-Latif, J. V. Reynolds, and D. Kelleher Low pH induces co-ordinate regulation of gene expression in oesophageal cells Carcinogenesis, February 1, 2006; 27(2): 319 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Vestergaard, M. Borre, S. S. Poulsen, E. Nexo, and N. Torring Plasma Levels of Trefoil Factors are Increased in Patients with Advanced Prostate Cancer Clin. Cancer Res., February 1, 2006; 12(3): 807 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, C. N. W. Rosenzweig, Z. Zhang, M. I. Canto, D. A. Brown, M. Hunter, C. Yeo, D. W. Chan, S. N. Breit, and M. Goggins Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 Clin. Cancer Res., January 15, 2006; 12(2): 442 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Brown, C. Stephan, R. L. Ward, M. Law, M. Hunter, A. R. Bauskin, J. Amin, K. Jung, E. P. Diamandis, G. M. Hampton, et al. Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis Clin. Cancer Res., January 1, 2006; 12(1): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X.-W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer Science, October 28, 2005; 310(5748): 644 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Berquin, Y. Min, R. Wu, H. Wu, and Y. Q. Chen Expression Signature of the Mouse Prostate J. Biol. Chem., October 28, 2005; 280(43): 36442 - 36451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Tan, D. Q. Naiman, L. Xu, R. L. Winslow, and D. Geman Simple decision rules for classifying human cancers from gene expression profiles Bioinformatics, October 15, 2005; 21(20): 3896 - 3904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Xu, A. C. Tan, D. Q. Naiman, D. Geman, and R. L. Winslow Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data Bioinformatics, October 15, 2005; 21(20): 3905 - 3911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J.M. Best, J. W. Gillespie, Y. Yi, G. V.R. Chandramouli, M. A. Perlmutter, Y. Gathright, H. S. Erickson, L. Georgevich, M. A. Tangrea, P. H. Duray, et al. Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy Clin. Cancer Res., October 1, 2005; 11(19): 6823 - 6834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, J. Yu, A. Sreekumar, S. Varambally, R. Shen, D. Giacherio, R. Mehra, J. E. Montie, K. J. Pienta, M. G. Sanda, et al. Autoantibody Signatures in Prostate Cancer N. Engl. J. Med., September 22, 2005; 353(12): 1224 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Goggins Molecular Markers of Early Pancreatic Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Bauskin, D. A. Brown, S. Junankar, K. K. Rasiah, S. Eggleton, M. Hunter, T. Liu, D. Smith, T. Kuffner, G. J. Pankhurst, et al. The Propeptide Mediates Formation of Stromal Stores of PROMIC-1: Role in Determining Prostate Cancer Outcome Cancer Res., March 15, 2005; 65(6): 2330 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D M Peehl Primary cell cultures as models of prostate cancer development Endocr. Relat. Cancer, March 1, 2005; 12(1): 19 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Santamaria, E. Castellanos, V. Gomez, P. Benedit, J. Renau-Piqueras, J. Morote, J. Reventos, T. M. Thomson, and R. Paciucci PTOV1 Enables the Nuclear Translocation and Mitogenic Activity of Flotillin-1, a Major Protein of Lipid Rafts Mol. Cell. Biol., March 1, 2005; 25(5): 1900 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Baek, J.-S. Kim, F. R. Jackson, T. E. Eling, M. F. McEntee, and S.-H. Lee Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells Carcinogenesis, December 1, 2004; 25(12): 2425 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Hobson, S. Netzel-Arnett, R. Szabo, S. M. Rehault, F. C. Church, D. K. Strickland, D. A. Lawrence, T. M. Antalis, and T. H. Bugge Mouse DESC1 Is Located within a Cluster of Seven DESC1-like Genes and Encodes a Type II Transmembrane Serine Protease That Forms Serpin Inhibitory Complexes J. Biol. Chem., November 5, 2004; 279(45): 46981 - 46994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Nicholson, H. F. Frierson, M. R. Conaway, J. M. Seraj, M. A. Harding, G. M. Hampton, and D. Theodorescu Profiling the Evolution of Human Metastatic Bladder Cancer Cancer Res., November 1, 2004; 64(21): 7813 - 7821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bibikova, D. Talantov, E. Chudin, J. M. Yeakley, J. Chen, D. Doucet, E. Wickham, D. Atkins, D. Barker, M. Chee, et al. Quantitative Gene Expression Profiling in Formalin-Fixed, Paraffin-Embedded Tissues Using Universal Bead Arrays Am. J. Pathol., November 1, 2004; 165(5): 1799 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Jang, H. J. Kang, J. R. Kim, and C. H. Yang Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis Carcinogenesis, October 1, 2004; 25(10): 1853 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Cheung, B. Woolcock, H. Adomat, M. Sutcliffe, T. C. Bainbridge, E. C. Jones, D. Webber, T. Kinahan, M. Sadar, M. E. Gleave, et al. Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis Cancer Res., September 1, 2004; 64(17): 5929 - 5933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ashida, H. Nakagawa, T. Katagiri, M. Furihata, M. Iiizumi, Y. Anazawa, T. Tsunoda, R. Takata, K. Kasahara, T. Miki, et al. Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer: Genome-wide Gene-expression Profiles of Prostate Cancers and PINs Cancer Res., September 1, 2004; 64(17): 5963 - 5972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E.H. Afar, V. Bhaskar, E. Ibsen, D. Breinberg, S. M. Henshall, J. G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer Mol. Cancer Ther., August 1, 2004; 3(8): 921 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Velasco, K. A. Gillis, Y. Li, E. L. Brown, T. M. Sadler, M. Achilleos, L. M. Greenberger, P. Frost, W. Bai, and Y. Zhang Identification and Validation of Novel Androgen-Regulated Genes in Prostate Cancer Endocrinology, August 1, 2004; 145(8): 3913 - 3924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. P. Yu, D. Landsittel, L. Jing, J. Nelson, B. Ren, L. Liu, C. McDonald, R. Thomas, R. Dhir, S. Finkelstein, et al. Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy J. Clin. Oncol., July 15, 2004; 22(14): 2790 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, and A. M. Chinnaiyan Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression PNAS, June 22, 2004; 101(25): 9309 - 9314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sreekumar, B. Laxman, D. R. Rhodes, S. Bhagavathula, J. Harwood, D. Giacherio, D. Ghosh, M. G. Sanda, M. A. Rubin, and A. M. Chinnaiyan Humoral Immune Response to {alpha}-Methylacyl-CoA Racemase and Prostate Cancer J Natl Cancer Inst, June 2, 2004; 96(11): 834 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rubin, S. Varambally, R. Beroukhim, S. A. Tomlins, D. R. Rhodes, P. L. Paris, M. D. Hofer, M. Storz-Schweizer, R. Kuefer, J. A. Fletcher, et al. Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer Cancer Res., June 1, 2004; 64(11): 3814 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Diamandis How Are We Going to Discover New Cancer Biomarkers? A Proteomic Approach for Bladder Cancer Clin. Chem., May 1, 2004; 50(5): 793 - 795. [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool: Opportunities and Potential Limitations Mol. Cell. Proteomics, April 1, 2004; 3(4): 367 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, P. Buckhaults, D. A. Brown, M. L. Zahurak, N. Sato, N. Fukushima, L. J. Sokoll, D. W. Chan, C. J. Yeo, R. H. Hruban, et al. Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers Clin. Cancer Res., April 1, 2004; 10(7): 2386 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kumar-Sinha, R. B. Shah, B. Laxman, S. A. Tomlins, J. Harwood, W. Schmitz, E. Conzelmann, M. G. Sanda, J. T. Wei, M. A. Rubin, et al. Elevated {alpha}-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer Am. J. Pathol., March 1, 2004; 164(3): 787 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lapointe, C. Li, J. P. Higgins, M. van de Rijn, E. Bair, K. Montgomery, M. Ferrari, L. Egevad, W. Rayford, U. Bergerheim, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer PNAS, January 20, 2004; 101(3): 811 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Stuart, W. Wachsman, C. C. Berry, J. Wang-Rodriguez, L. Wasserman, I. Klacansky, D. Masys, K. Arden, S. Goodison, M. McClelland, et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer PNAS, January 13, 2004; 101(2): 615 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J Evans {alpha}-Methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies J. Clin. Pathol., December 1, 2003; 56(12): 892 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Schulke, O. A. Varlamova, G. P. Donovan, D. Ma, J. P Gardner, D. M. Morrissey, R. R. Arrigale, C. Zhan, A. J. Chodera, K. G. Surowitz, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy PNAS, October 28, 2003; 100(22): 12590 - 12595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Gordon, W. G. Richards, D. J. Sugarbaker, M. T. Jaklitsch, and R. Bueno A Prognostic Test for Adenocarcinoma of the Lung From Gene Expression Profiling Data Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 905 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Tanyi, Y. Hasegawa, R. Lapushin, A. J. Morris, J. K. Wolf, A. Berchuck, K. Lu, D. I. Smith, K. Kalli, L. C. Hartmann, et al. Role of Decreased Levels of Lipid Phosphate Phosphatase-1 in Accumulation of Lysophosphatidic Acid in Ovarian Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3534 - 3545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Liu, A. R. Bauskin, J. Zaunders, D. A. Brown, S. Pankurst, P. J. Russell, and S. N. Breit Macrophage Inhibitory Cytokine 1 Reduces Cell Adhesion and Induces Apoptosis in Prostate Cancer Cells Cancer Res., August 15, 2003; 63(16): 5034 - 5040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.A. Schulz, M. Burchardt, and M.V. Cronauer Molecular biology of prostate cancer Mol. Hum. Reprod., August 1, 2003; 9(8): 437 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Lee, Y. Yang, S. J. Lee, K.-Y. Kim, T. H. Koo, S. M. Shin, K. S. Song, Y. H. Lee, Y.-J. Kim, J. J. Lee, et al. Macrophage Inhibitory Cytokine-1 Induces the Invasiveness of Gastric Cancer Cells by Up-Regulating the Urokinase-type Plasminogen Activator System Cancer Res., August 1, 2003; 63(15): 4648 - 4655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rossi, E. Graner, P. Febbo, L. Weinstein, N. Bhattacharya, T. Onody, G. Bubley, S. Balk, and M. Loda Fatty Acid Synthase Expression Defines Distinct Molecular Signatures in Prostate Cancer Mol. Cancer Res., August 1, 2003; 1(10): 707 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Grzmil, P. Thelen, B. Hemmerlein, S. Schweyer, S. Voigt, D. Mury, and P. Burfeind Bax Inhibitor-1 Is Overexpressed in Prostate Cancer and Its Specific Down-Regulation by RNA Interference Leads to Cell Death in Human Prostate Carcinoma Cells Am. J. Pathol., August 1, 2003; 163(2): 543 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Vanaja, J. C. Cheville, S. J. Iturria, and C. Y. F. Young Transcriptional Silencing of Zinc Finger Protein 185 Identified by Expression Profiling Is Associated with Prostate Cancer Progression Cancer Res., July 15, 2003; 63(14): 3877 - 3882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Iczkowski and C. G. Pantazis Overexpression of NSAID-Activated Gene Product in Prostate Cancer International Journal of Surgical Pathology, July 1, 2003; 11(3): 159 - 166. [Abstract] [PDF]
|
|
|
|
|
|
D. A. Brown, R. L. Ward, P. Buckhaults, T. Liu, K. E. Romans, N. J. Hawkins, A. R. Bauskin, K. W. Kinzler, B. Vogelstein, and S. N. Breit MIC-1 Serum Level and Genotype: Associations with Progress and Prognosis of Colorectal Carcinoma Clin. Cancer Res., July 1, 2003; 9(7): 2642 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Shen-Ong, Y. Feng, and D. A. Troyer Expression Profiling Identifies a Novel {alpha}-Methylacyl-CoA Racemase Exon with Fumarate Hydratase Homology Cancer Res., June 15, 2003; 63(12): 3296 - 3301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Rhodes, M. G. Sanda, A. P. Otte, A. M. Chinnaiyan, and M. A. Rubin Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer J Natl Cancer Inst, May 7, 2003; 95(9): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Singh, S. Sadacharan, S. Su, A. Belldegrun, S. Persad, and G. Singh Overexpression of Vimentin: Role in the Invasive Phenotype in an Androgen-independent Model of Prostate Cancer Cancer Res., May 1, 2003; 63(9): 2306 - 2311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Gordon, R. V. Jensen, L.-L. Hsiao, S. R. Gullans, J. E. Blumenstock, W. G. Richards, M. T. Jaklitsch, D. J. Sugarbaker, and R. Bueno Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma J Natl Cancer Inst, April 16, 2003; 95(8): 598 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Welsh, L. M. Sapinoso, S. G. Kern, D. A. Brown, T. Liu, A. R. Bauskin, R. L. Ward, N. J. Hawkins, D. I. Quinn, P. J. Russell, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum PNAS, March 18, 2003; 100(6): 3410 - 3415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Santamaria, P. L. Fernandez, X. Farre, P. Benedit, J. Reventos, J. Morote, R. Paciucci, and T. M. Thomson PTOV-1, a Novel Protein Overexpressed in Prostate Cancer, Shuttles between the Cytoplasm and the Nucleus and Promotes Entry into the S Phase of the Cell Division Cycle Am. J. Pathol., March 1, 2003; 162(3): 897 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Philip-Couderc, F. Smih, M. Pelat, C. Vidal, P. Verwaerde, A. Pathak, S. Buys, M. Galinier, J.-M. Senard, and P. Rouet Cardiac Transcriptome Analysis in Obesity-Related Hypertension Hypertension, March 1, 2003; 41(3): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V.-M. Wasenius, S. Hemmer, E. Kettunen, S. Knuutila, K. Franssila, and H. Joensuu Hepatocyte Growth Factor Receptor, Matrix Metalloproteinase-11, Tissue Inhibitor of Metalloproteinase-1, and Fibronectin Are Up-Regulated in Papillary Thyroid Carcinoma: A cDNA and Tissue Microarray Study Clin. Cancer Res., January 1, 2003; 9(1): 68 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Xin, D. R. Rhodes, C. Ingold, A. M. Chinnaiyan, and M. A. Rubin Dysregulation of the Annexin Family Protein Family Is Associated with Prostate Cancer Progression Am. J. Pathol., January 1, 2003; 162(1): 255 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bar-Shira, J. H. Pinthus, U. Rozovsky, M. Goldstein, W. R. Sellers, Y. Yaron, Z. Eshhar, and A. Orr-Urtreger Multiple Genes in Human 20q13 Chromosomal Region Are Involved in an Advanced Prostate Cancer Xenograft Cancer Res., December 1, 2002; 62(23): 6803 - 6807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Srikantan, M. Valladares, J. S. Rhim, J. W. Moul, and S. Srivastava HEPSIN Inhibits Cell Growth/Invasion in Prostate Cancer Cells Cancer Res., December 1, 2002; 62(23): 6812 - 6816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Gildea, M. J. Seraj, G. Oxford, M. A. Harding, G. M. Hampton, C. A. Moskaluk, H. F. Frierson, M. R. Conaway, and D. Theodorescu RhoGDI2 Is an Invasion and Metastasis Suppressor Gene in Human Cancer Cancer Res., November 15, 2002; 62(22): 6418 - 6423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dash, I. P. Maine, S. Varambally, R. Shen, A. M. Chinnaiyan, and M. A. Rubin Changes in Differential Gene Expression because of Warm Ischemia Time of Radical Prostatectomy Specimens Am. J. Pathol., November 1, 2002; 161(5): 1743 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Frierson Jr, A. K. El-Naggar, J. B. Welsh, L. M. Sapinoso, A. I. Su, J. Cheng, T. Saku, C. A. Moskaluk, and G. M. Hampton Large Scale Molecular Analysis Identifies Genes with Altered Expression in Salivary Adenoid Cystic Carcinoma Am. J. Pathol., October 1, 2002; 161(4): 1315 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Velasco, S. Cal, V. Quesada, L. M. Sanchez, and C. Lopez-Otin Matriptase-2, a Membrane-bound Mosaic Serine Proteinase Predominantly Expressed in Human Liver and Showing Degrading Activity against Extracellular Matrix Proteins J. Biol. Chem., September 27, 2002; 277(40): 37637 - 37646. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
) and 9 normal (
) samples. Error bars, 99% confidence intervals. Shown are 20 genes ranked most highly by a hybrid metric 
